Corticosteroid inhalers for copd

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of AirDuo™ RespiClick® and its Authorized Generic, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

Corticosteroid inhalers for copd

corticosteroid inhalers for copd

Media:

corticosteroid inhalers for copdcorticosteroid inhalers for copdcorticosteroid inhalers for copdcorticosteroid inhalers for copdcorticosteroid inhalers for copd